Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017 after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, February 23, 2017 at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 60580589.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
Company Contact: Heather Rowe Investor Relations 415-365-5737 [email protected]
